High cut-off point membranes in septic acute renal failure: A systematic review

International Journal of Artificial Organs

Volumn 30, Issue 12, 2007, Pages 1031-1041

  Haase, M ^a,b   Bellomo, Rinaldo ^a   Morger, S ^b   Baldwin, I ^a   Boyce, N ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Acute renal failure; Blood purification; Cytokines; High cut off point membranes; Renal replacement therapy; Sepsis

Indexed keywords

ANIMALS; BACTERIOLOGY; BLOOD; MEMBRANES; PHYSIOLOGICAL MODELS; SEARCH ENGINES;

ACUTE RENAL FAILURE; BLOOD PURIFICATION; CLINICAL STUDY; CYTOKINES; HIGH CUT-OFF POINT MEMBRANE; MEMBRANE-BASED; PHYSIOLOGICAL EFFECTS; RENAL FAILURE; RENAL REPLACEMENT THERAPIES; SEPSIS;

PURIFICATION;

CYTOKINE; HYPERTENSIVE AGENT;

ACUTE KIDNEY FAILURE; ARTIFICIAL MEMBRANE; BACTEREMIA; CELL FUNCTION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; ENDOTOXEMIA; EQUIPMENT DESIGN; EX VIVO STUDY; HEMODIAFILTRATION; HEMODIALYSIS; HEMOFILTRATION; HUMAN; IMMUNOCOMPETENT CELL; INFORMATION RETRIEVAL; MEDLINE; NONHUMAN; PATIENT SAFETY; PLASMA CLEARANCE; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RENAL REPLACEMENT THERAPY; REVIEW; RISK REDUCTION; SEPSIS; SURVIVAL RATE; SYSTEMATIC REVIEW;

EID: 38849175509     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880703001202     Document Type: Review

References (61)

1. Bagshaw SM, Laupland KB, Doig CJ, et al. Prognosis for long term survival and renal recovery in critically ill patients with severe acute renal failure: a population based study. Crit Care 2005; 9: R 700-9.
2. Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients. A multinational, multicenter study. JAMA 2005; 294: 813-8.
3. Schrier RW, Wang W. Acute renal failure and sepsis. N Engl J Med 2004; 351:159-69.
4. Wan L, Bellomo R, Di Giantomasso D, Ronco C. The pathogenesis of septic acute renal failure. Curr Opin Crit Care 2003; 9: 496-502.
5. Parrillo JE. Pathogenetic mechanisms of septic shock. N Engl J Med 1993; 328: 1471-7.
6. Levy M, Fink M, Marshall J, Abraham E, Angus D, Cook D, Cohen J, Opal S, Vincent J, Ramsay G, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003, 31: 1250-6.
7. Pinsky MR, Vincent JL, Deviere J, et al. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest 1993; 103: 565-75.
8. Hack CE, Aarden LA, Thijs LG. Role of cytokines in sepsis. Adv Immunol 1997; 66: 101-95.
9. Szabo C, Southan GJ, Thiemermann C. Beneficial effects and improved survival in rodent models of septic shock with S-methylisothiourea sulfate, a potent and selective inhibitor of inducible nitric oxide synthase. Proc Natl Acad Sci U S A 1994; 91: 12472-6.
10. Titheradge MA. Nitric oxide in septic shock. Biochim Biophys Acta 1999; 1411: 437-55.
11. Bertani T, Abbate M, Zoja C, et al. Tumor necrosis factor induces glomerular damage in the rabbit. Am J Pathol 1989; 134: 419-30.
12. Messmer UK, Briner VA, Pfeilschifter J. Basic fibroblast growth factor selectively enhances TNF-alpha-induced apoptotic cell death in glomerular endothelial cells: effects on apoptotic signaling pathways. J Am Soc Nephrol 2000; 11: 2199-2211.
13. Lieberthal W, Triaca V, Levine J. Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis. Am J Physiol 1996; 270: F700-8.
14. Mariano F, Tetta C, Guida G, Triolo G, Camussi G. Hemofiltration reduces the serum priming activity on neutrophil chemiluminescence in septic patients. Kidney Int 2001; 60: 1598-1605.
15. Hirano T, Kishimoto T, et al. Biological and clinical aspects of IL-6. In: Kishimoto T (ed.). Molecular Biology and Immunology. Basel: Karger, 1992. p 153-204.
16. Hamilton G, Hofbauer S Hamitlon B. Endotoxin, TNF-a, IL-6 and parameters of the cellular immune system in patients with intraabdominal sepsis. Scand J Infect Dis 1992; 24: 361-8.
17. Waage A, Brandtzaeg P, Halstensen A, Kierulf P, Espevik T. The complex pattern of cytokines in serum from patients with meningococcal septic shock: Association between Interleukin 6, Interleukin 1 and septic shock. J Exp Med 1989; 169: 333-8.
18. Meldrum DR, Ayala A, Chaudry IH. Energetics of lymphocyte 'burnout' in late sepsis: adjuvant treatment with ATPMgC12 improves energetics and decreases lethality. J Surg Res 1994; 56: 537-42.
19. Volk HD, Reinke P, Krausch D, et al. Monocyte deactivation: rationale for a new therapeutic strategy in sepsis. Intensive Care Med; 1996 (Suppl 4): S474-8.
20. Toft P, Brix-Christensen V, Baech J, et al. Effect of hemodia-filtration and sepsis on chemotaxis of granulocytes and the release of IL-8 and IL-10. Acta Anaesthesiol Scand 2002; 46: 138-44.
21. Heidecke CD, Hensler T, Weighardt H, et al. Selective defects of T-lymphocytes in patients with lethal intraabdominal infection. Am J Surg 1999; 178: 288-92.
22. Dinarello CA. Proinflammatory cytokines. Chest 2000; 118: 503-8.
23. Marshall JC. Such stuff as dreams are made on: mediator-directed therapy in sepsis. Nat Rev Drug Discov 2003; 2: 391-405.
24. Glauser MP. The inflammatory cytokines. New developments in the pathophysiology and treatment of septic shock. Drugs 1996; 52 (Suppl 2): S9-17.
25. Kellum JA, Bellomo R, Mehta R, Ronco C. Blood purification in non-renal critical illness, Blood Purif 2003; 21: 6-13.
26. Ronco C, Tetta C, Mariano F, et al. Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis. Int J Artif Organs 2003; 27: 792-801.
27. Winchester JF, Kellum JA, Ronco C, et al. Sorbents in acute renal failure and the systemic inflammatory response syndrome. Blood Purif 2003; 21: 79-84.
28. Bellomo R, Tipping P, Boyce N. Continuous veno-venous hemofiltration with dialysis removes cytokines from the circulation of septic patients. Crit Care Med 1993; 21: 522-6.
29. Sanchez-Izquierdo JA, Perez Vela JL, Lozano Quintana MJ, Alted Lopez E, Ortuno de Solo B, Ambros Checa A. Cytokine clearance during venovenous hemofiltration in the trauma patient. Am J Kidney Dis 1997; 30: 483-8.
30. De Vriese AS, Colardyn FA, Philippe JJ, Vanholder RC, De Sutter JH, Lameire NH. Cytokine removal during continuous hemofiltration in septic patients. J Am Soc Nephrol 1999; 10: 846-53.
31. Hoffmann JN, Hartl WH, Deppisch R, Faist E, Jochum M, Inthorn D. Hemofiltration in human sepsis: evidence for elimination of immunomodulatory substances. Kidney Int 1995; 48: 1563-70.
32. Gasche Y, Pascual M, Suter PM, Favre H, Chevrolet JC, Schifferli JA. Complement depletion during haemofiltration with polyacrilonitrile membranes. Nephrol Dial Transplant 1996; 11: 117-9.
33. Kellum JA, Johnson JP, Kramer D, Palevsky P, Brady JJ, Pinsky MR. Diffusive vs. convective therapy: effects on mediators of inflammation in patient with severe systemic inflammatory response syndrome. Crit Care Med 1998; 26: 1995-2000.
34. Braun N, Rosenfeld S, Giolai M, et al. Effect of continuous hemodiafiltration on IL-6, TNF-alpha, C3a, and TCC in patients with SIRS/ septic shock using two different membranes. Contrib Nephrol 1995; 116: 89-98.
35. Sander A, Armbruster W, Sander B, Daul AE, Lange R, Peters J. Hemofiltration increases IL-6 clearance in early systemic inflammatory response syndrome but does not alter IL-6 and TNF-a plasma concentrations. Intensive Care Med 1997; 23: 878-84.
36. Cole L, Bellomo R, Hart G, et al. A phase II randomized, controlled trial of continuous hemofiltration in sepsis. Crit Care Med 2002; 30: 100-6.
37. Heering P, Morgera S, Schmitz FJ, et al. Cytokine removal and cardiovascular haemodynamics in septic patients with continuous venovenous haemofiltration. Intensive Care Med 1997; 23: 288-96.
38. Ronco C, Bellomo R, Homel P, et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 2000; 356: 26-30.
39. Bellomo R, Kellum JA, Gandhi CR, Pinsky MR, Ondulik B. The effect of intensive plasma water exchange by hemofiltration on hemodynamics and soluble mediators in canine endotoxemia. Am J Respir Crit Care Med 2000; 161: 1429-36.
40. Honore PM, Jamez J, Wauthier M, et al. Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock. Crit Care Med 2000; 28: 3581-7.
41. Cole L, Bellomo R, Journois D, Davenport P, Baldwin I, Tipping P. High-volume haemofiltration in human septic shock. Intensive Care Med 2001; 27: 978-86.
42. Reeves JH, Butt WW, Shann F, et al. Continuous plasmafiltration in sepsis syndrome. Plasmafiltration in Sepsis Study Group. Crit Care Med 1999; 27:2096-104.
43. Busund R, Koukline V, Utrobin U, Nedashkovsky E. Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial. Intensive Care Med 2002; 28: 1434-9.
44. Morgera S, Rocktaschel J, Haase M, et al. Intermittent high permeability hemofiltration in septic patients with acute renal failure. Intensive Care Med 2003; 29: 1989-95.
45. Morgera S, Haase M, Rocktaschel J, et al. High permeability haemofiltration improves peripheral blood mononuclear cell proliferation in septic patients with acute renal failure. Nephrol Dial Transplant 2003; 18: 2570-6.
46. Morgera S, Haase M, Rocktaschel J, et al. Intermittent high-permeability hemofiltration modulates inflammatory response in septic patients with multiorgan failure. Nephron Clin Pract 2003; 94: c75-80.
47. Morgera S, Slowinski T, Melzer C, et al. Renal replacement therapy with high-cutoff hemofilters: Impact of convection and diffusion on cytokine clearances and protein status. Am J Kidney Dis 2004; 43: 444-53.
48. Morgera S, Haase M, Kuss T, et al. Pilot study on the effects of high cutoff hemofiltration on the need for norepinephrine in septic patients with acute renal failure. Crit Care Med 2006; 34: 2099-104.
49. Haase M, Bellomo R, Baldwin I, et al. Hemodialysis Membrane With a High Molecular Weight Cut-Off and Cytokine Levels in Sepsis Complicated by Acute Renal Failure: A Phase I Randomized Trial. Am J Kidney Dis 2007 (in press).
50. Lee WC, Uchino S, Fealy N, et al. Super high flux hemodialysis at high dialysate flows: an ex vivo assessment. Int J Artif Organs 2004; 27: 24-8.
51. Uchino S, Bellomo R, Morimatsu H, et al. Cytokine dialysis: an ex vivo study. ASAIO J 2002; 48: 650-3.
52. Morgera S, Klonower D, Rocktaschel J, et al. TNF-alpha elimination with high cut-off haemofilters: a feasible clinical modality for septic patients? Nephrol Dial Transplant 2003; 18: 1361-9.
53. Lee PA, Weger GW, Pryor RW, Matson JR. Effects of filter pore size on efficacy of continuous arteriovenous hemofiltration therapy for Staphylococcus aureus-induced septicemia in immature swine. Crit Care Med 1998; 26: 730-7.
54. Kline JA, Gordon BE, Williams C, Blumenthal S, Watts JA, Diaz-Buxo J. Large-pore hemodialysis in acute endotoxin shock. Crit Care Med 1999; 27: 588-96.
55. Uchino S, Bellomo R, Goldsmith D, et al. Super high flux hemofiltration: a new technique for cytokine removal. Intensive Care Med 2002; 28: 651-5.
56. Mariano F, Fonsato V, Lanfranco G, P et al. Tailoring highcut-off membranes and feasible application in sepsis-associated acute renal failure: in vitro studies. Nephrol Dial Transplant 2005; 20: 1116-26.
57. Uchino S, Bellomo R, Goldsmith D, et al. Cytokine removal with a large pore cellulose triacetate filter: an ex vivo study. Int J Artif Organs 2002; 25: 27-32.
58. Delanaye P, Lambermont B, Dogne JM, et al. Confirmation of high cytokine clearance by hemofiltration with a cellulose triacetate membrane with large pores: an in vivo study. Int J Artif Organs 2006; 29: 944-8.
59. Lambermont B, Delanaye P, Dogne JM, et al. Large-pore membrane hemofiltration increases cytokine clearance and improves right ventricular-vascular coupling during endotoxic shock in pigs. Artif Organs 2006; 30: 560-4.
60. Bordoni V, Bolgan I, Brendolan A, et al. Caspase-3 and -8 activation and cytokine removal with a novel cellulose triacetate super-permeable membrane in an in vitro sepsis model. Int J Artif Organs 2003; 26: 897-905.
61. Huber-Lang MS, Sarma JV, McGuire SR, et al. Protective effects of anti-C5a peptide antibodies in experimental sepsis. FASEB J 2001; 15: 568-70.